| Peter Jeffrey Ogawa, PHARMD | |
|
7257 N Fresno St, Fresno, CA 93720-2950 | |
| (559) 451-3632 | |
| (559) 431-5827 |
| Full Name | Peter Jeffrey Ogawa |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 7257 N Fresno St, Fresno, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194849679 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 39724 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Peter Jeffrey Ogawa, PHARMD 680 E Woodhaven Ln, Fresno, CA 93720-1286 Ph: (559) 434-6550 | Peter Jeffrey Ogawa, PHARMD 7257 N Fresno St, Fresno, CA 93720-2950 Ph: (559) 451-3632 |
News Archive
Today, the National Medical Association (NMA) and the National Black Nurses Association (NBNA) released a consensus report on RSV. Concerned that recent clinical guidelines published by the American Academy of Pediatrics Committee of Infectious Disease (AAP/COID) may leave some infants unprotected from RSV, the NMA/NBNA RSV Consensus Panel recommended that additional research be conducted to ensure that physicians provide the maximum protection to infants and children at risk of RSV.
Researchers from Harvard Medical School and Brandeis University have successfully completed a full-genome RNAi screen in neurons, showing what types of genes are necessary for brain development. Details of the screen and its novel methodology are published July 4th in the open-access journal PLoS Genetics.
Surgical Information Systems ('SIS'), a leader in perioperative information systems, announced today that Mountain States Health Alliance (MSHA) has completed implementation of Perioperative Management by SIS for organizations using Soarian® Clinicals from Siemens Healthcare in two facilities: Johnson City Medical Center and Johnston Memorial Hospital.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.
› Verified 5 days ago
Dr. Alis Filipioglu-fago, PHARM. D., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7535 N Palm Ave Ste 101, Fresno, CA 93711 Phone: 559-432-9800 Fax: 559-432-2349 | |
Dr. Lynice Fou, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-3305 Fax: 559-448-3350 | |
Yuri Cho, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 740 W Alluvial Ave, Suite 101, Fresno, CA 93711 Phone: 800-797-3543 | |
Johnny Quoc Nguyen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7015 N West Ave, Fresno, CA 93711 Phone: 559-440-1404 Fax: 559-440-1407 | |
Penang Pham, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6074 N 1st St, Fresno, CA 93710 Phone: 559-431-5231 | |
Dr. Jagdip Jaspal, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 504 East Herndon Ave Suite 101, Fresno, CA 93720 Phone: 559-438-9888 | |
Dr. James Michael Winton, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4233 E Tulare St, Fresno, CA 93702 Phone: 559-255-3071 |